Table 3.

Association between CA 125, HE4, RMI and ROMA values and risk of malignancy

Tumor marker	Histopathology			Total number of cases (n = 94)	Statistical significance
	Benign	Borderline	Malignant
CA125 values (pre-menopausal)
< 200 U/ml	63 (77.8%)	3 (3.7%)	15 (18.5%)	81	p = 0.002
> 200 U/ml	4 (30.8%)	1 (7.7%)	8 (61.5%)	13
CA125 values (post-menopausal)
< 35 U/ml	10 (76.9%)	2 (15.4%)	1 (7.7%)	13	p = 0.002
> 35 U/ml	18 (34%)	2 (3.8%)	33 (62.3%)	53
HE4 values (pre-menopausal)
< 70 pmol/L	63 (94%)	1 (1.5%)	3 (4.5%)	67 (100.0%)	p = 0.001
> 70 pmol/L	4 (14.8%)	3 (11.1%)	20 (74.1%)	27 (100.0%)
HE4 values (post-menopausal)
< 140 pmol/L	27 (75%)	2 (5.7%)	7 (19.4%)	36 (100.0%)	p = 0.001
> 140 pmol/L	1 (3.3%)	2 (6.7%)	27 (90.0%)	29 (100.0%)
RMI values
< 200	66 (89.2%)	2 (2.7%)	6(8.1%)	74	p = 0.000
> 200	29 (33.7%)	6 (7.0%)	51 (59.3%)	86
ROMA values (pre-menopausal)
< 11.4%	56 (94.9%)	1 (1.7%)	2 (3.7%)	59 (100.0%)	p = 0.001
≥ 11.4%	11 (31.4%)	3 (8.6%)	21 (60%)	35 (100.0%)
ROMA values (post-menopausal)
< 22.9	22 (88%)	1 (4%)	2 (8%)	25 (100.0%)	p = 0.001
> 22.9	6 (14.6%)	3 (7.3%)	32 (78%)	41 (100.0%)